EUVIMEDEUVIMED entdecken
Crossref

Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting

Jouko Levijoki iD, Lasse Saloranta, Johanna Tuunainen, Janne Kaskinoro, Sari Pappinen, Sandra Nourry, Anne-Marie Betat, Anne Maurin, Maarit Pakarinen, Sari Häkkinen, Johanna Tervapuro, Hertta Pihlasvaara und 2 weitere

The Journal of Pharmacology and Experimental Therapeutics · 2023

DOI: 10.1124/jpet.122.001444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023. Verfasst von Jouko Levijoki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.…. Hauptthemen laut MEDLINE: Cisplatin, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer treatments are frequently associated with nausea and vomiting despite greatly improved preventive medication. Administration of antinausea agents as eye drops might provide easy and rapid access to the systemic circulation for prevention of nausea and vomiting and for the treatment of breakthrough nausea, but the ocular administration route has rarely been evaluated. Palonosetron is a second-generation 5-hydroxytryptamine 3 receptor antagonist approved for prevention and treatment of chemotherapy-induced nausea and vomiting. We compared ocular administration of palonosetron to non-active vehicle eye drops and to intravenous palonosetron in the prevention of cisplatin-induced nausea and vomiting in beagle dogs. Palonosetron ocular drops at the dose of 30 µg/kg reduced cumulative nausea over time as measured with the area under the visual analog scale curve by 98% compared with the vehicle and reduced nausea-associated dog behavior by 95%. Vomiting was completely prevented with repeated palonosetron ocular dosing. Hydroxypropyl-β-cyclodextrin (HP-β-CD) palonosetron formulation was well tolerated locally at the palonosetron concentration of 3 mg/ml. Absorption of palonosetron from eye drops was fast. Ten minutes after ocular administration, palonosetron plasma concentrations were similar compared with intravenous administration, and remained similar for six hours. We conclude that palonosetron is rapidly absorbed into the systemic circulation from eye drops. Ocularly administered palonosetron was well tolerated in the HP-β-CD formulation and was highly effective in the prevention of cisplatin-induced nausea and vomiting. Evaluation of the safety and efficacy of ocular administration of palonosetron is warranted in the prevention and treatment of chemotherapy-induced nausea and vomiting in clinical trials. SIGNIFICANCE STATEMENT: Palonosetron, an effective and well-tolerated antiemetic drug was rapidly absorbed into the systemic blood circulation when administered as eye drops. The achieved palonosetron blood concentrations prevented cisplatin-induced nausea and vomiting in beagle dogs. Palonosetron eye drops might provide an easy and quick method for administering palonosetron when parenteral administration is desired and intravenous administration is not feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinAntineoplastic AgentsAnimalsDogsPalonosetron2-Hydroxypropyl-beta-cyclodextrinAdministration, OphthalmicIsoquinolinesQuinuclidinesVomitingNauseaDexamethasone

Substanzen

PalonosetronCisplatin2-Hydroxypropyl-beta-cyclodextrinIsoquinolinesQuinuclidinesAntineoplastic AgentsDexamethasone

Autor:innen und Institutionen

  • Orion Corporation Orion Pharma, Espoo, Finland(J.L., L.S., J.T., J.K., S.P., M.P., S.H., J.T., H.P., H.J.); Biotrial Pharmacology, Rennes, France (S.N., A-M.B., A.M., C.D.L.R.); and Department of Oncology, Helsinki Univ…

ORCID-Profile: Jouko Levijoki

Zitieren

APA

Levijoki, J., Saloranta, L., Tuunainen, J., Kaskinoro, J., Pappinen, S., Nourry, S., Betat, A. M., Maurin, A., Pakarinen, M., Häkkinen, S., Tervapuro, J., Pihlasvaara, H., Drieu La Rochelle, C., & Joensuu, H. (2023). Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.122.001444

Vancouver

Levijoki J, Saloranta L, Tuunainen J, Kaskinoro J, Pappinen S, Nourry S, et al. Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting. The Journal of Pharmacology and Experimental Therapeutics. 2023. doi:10.1124/jpet.122.001444

BibTeX
@article{Levijoki2023,
  author = {Levijoki, Jouko and Saloranta, Lasse and Tuunainen, Johanna and Kaskinoro, Janne and Pappinen, Sari and Nourry, Sandra and Betat, Anne-Marie and Maurin, Anne and Pakarinen, Maarit and Häkkinen, Sari and Tervapuro, Johanna and Pihlasvaara, Hertta and Drieu La Rochelle, Christophe and Joensuu, Heikki},
  title = {Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2023},
  doi = {10.1124/jpet.122.001444}
}
Kostenlos starten →